HPTN Publications

Moore JR, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Bekker LG, Mgodi NM, El-Sadr W, Cohen MS, Celum CL, Dimitrov D . Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression [HPTN 082]. Journal of Acquired Immune Deficiency Syndromes. 2020, 85: 423-429

Moshoette T, Papathanasopoulos MA, Killick MA . HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. J Virol. 2022, 19: 143

Mubekapi-Musadaidzwa C, Wademan D, Peton N, Hendricks P, Carolus G, Mbaezue R, Kelley KF, Kruger J, Jennings K, Grobbelaar N, Louis F, Beyers N, Ayles H, Fidler S, Hayes R, Bock P, Hoddinott G . Motivating people living with HIV to initiate antiretroviral treatment outside national guidelines in three clinics in the HPTN 071 (PopART) trial, South Africa. 2021

Mulubwa C, Hensen B, Phiri MM, Shanaube K, Schaap AJ, Floyd S, Phiri CR, Bwalya C, Bond V, Simwinga M, Mwenge L, Fidler S, Hayes R, Mwinga A, Ayles H, for the HPTN 071 Study Team . Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities. Lancet HIV. 2019, 6: e81-e92

Myron S. Cohen, Lawrence Corey, Cohen MS, Corey L . Broadly neutralizing antibodies to prevent HIV-1. 2017, 358: 46-47

Naranbhai V, Moodley D, Chipato T, Stranix-Chibanda L, Nakabaiito C, Kamateeka M, Musoke P, Manji K, George K, Emel LM, Richardson P, Andrew P, Fowler M, Fletcher H, McShane H, Coovadia HM, Hill AV; HPTN 046 Protocol Team . The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women.. Journal of Acquired Immune Deficiency Syndromes. 2014, 67: 573-5

Ndimande-Khoza MN, Scorgie F, Delany-Moretlwe S, Selin A, Twine R, Kahn K, Pettifor A, MacPhail C . The impact of conditional cash transfers for HIV prevention on peer relationships: perspectives from female recipients and non-recipients in HPTN 068. BMC Public Health. 2022, 22: 2230

Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP . Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis [HPTN 083]. Ann Intern Med. 2022, 175: 479-489